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Abstract: Non-alcoholic fatty liver disease, deﬁ  ned as the presence of macrovascular steatosis 
in the presence of less than 20 gm of alcohol ingestion per day, is the most common liver disease 
in the USA. It is most commonly associated with insulin resistance/type 2 diabetes mellitus 
and obesity. It is manifested by steatosis, steatohepatitis, cirrhosis, and, rarely, hepatocellular 
carcinoma.
Hepatic steatosis results from an imbalance between the uptake of fat and its oxidation 
and export. Insulin resistance, predisposing to lipolysis of peripheral fat with mobilization to 
and uptake of fatty acids by the liver, is the most consistent underlying pathogenic factor. It is 
not known why some patients progress to cirrhosis; however, the induction of CYP 2E1 with 
generation of reactive oxygen species appears to be important.
Treatment is directed at weight loss plus pharmacologic therapy targeted toward insulin 
resistance or dyslipidemia. Bariatric surgery has proved effective. While no pharmacologic 
therapy has been approved, emerging data on thiazolidinediones have demonstrated improve-
ment in both liver enzymes and histology. There are fewer, but promising data, with statins 
which have been shown to be hepatoprotective in other liver diseases. The initial enthusiasm 
for ursodeoxycholic acid has not been supported by histologic studies.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is deﬁ  ned by the presence of hepatic 
macrovesicular steatosis in the presence of less than 20 g of alcohol ingestion per 
day. It is the most common liver disease in the US (Clark et al 2002; Browning et al 
2004; McCullough 2005) and refers to a broad spectrum of liver disease which varies 
from bland steatosis (NAFLD) to steatohepatitis (NASH) to progressive ﬁ  brosis and, 
ultimately, cirrhosis with portal hypertension (Silverman et al 1989; Powell et al 
1990; Matteoni et al 1999; Marchesini et al 2003). Hepatocellular carcinoma has 
been reported in those with cirrhosis (Bugianesi et al 2002; Caldwell et al 2004).
Epidemiology and natural history
NAFLD was largely unknown prior to 1980 but is now recognized as the most common 
chronic liver disease in the US and many other parts of the world. The prevalence of 
NAFLD, as determined by population studies using ultrasound and serum enzymes, 
is estimated at 23%–30% (Clark et al 2002). The prevalence is expected to increase 
as the incidence of obesity and type 2 diabetes mellitus increases. While such studies 
do not distinguish NASH, the progressive form of the disease, from bland steatosis, it 
has been suggested that the prevalence of NASH is 5.7%–17% of the general popula-
tion (McCullough 2005).
NAFLD may lead to NASH, cirrhosis and in some cases, hepatocellular carcinoma 
(Powell et al 1990; Matteoni et al 1999; Bugianesi et al 2002). Fifty percent of patients 
with NAFLD have NASH and 19% have cirrhosis at the time of diagnosis (Silverman 
et al 1989; Silverman et al 1990; Marchesini et al 2003). Once cirrhosis develops 
30%–40% of patients will die of liver failure over a 10 year period (McCullough 2005), Therapeutics and Clinical Risk Management 2007:3(6) 1154
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a rate that is at least equal to that seen with hepatitis C (Hui 
et al 2003). Hepatocellular carcinoma is an increasingly rec-
ognized outcome (Powell et al 1990; Bugianesi et al 2002). 
Why some patients develop progressive disease while most 
do not remains to be determined, although genetic factors 
may be involved (Struben et al 2000; Willner et al 2001).
Etiology
The precise etiology of NAFLD is unknown but there is a 
strong association with obesity, the metabolic/insulin resis-
tance syndrome and dyslipidemia (Table 1). Most patients 
with NASH are obese and there is increasing evidence of an 
obesity epidemic in the US and elsewhere (Flegal et al 1998; 
Calle et al 1999; Livingston 2000; James et al 2004). It is 
estimated that 70%–80% of obese subjects have NAFLD with 
15%–20% having NASH (Bugianesi et al 2002). A recent 
study demonstrated that 88% of patients with NASH have the 
insulin resistance syndrome (Marchesini et al 2003). Type 2 
diabetes (DM2) is associated with NAFLD in 30%–80% of 
subjects (Silverman et al 1989, 1990; Marchesini et al 1999) 
and NAFLD is present in virtually 100% of patients with 
combined DM2 and obesity (Wanless and Lentz 1990).
In patients with diabetes, the standardized mortality ratio 
for cirrhosis (2.52) is greater than that for cardiovascular 
disease (1.34) (de Marco et al 1999).
Dyslipidemia is present in 50%–60% of individuals with 
NAFLD. Hypercholesterolemia alone is associated with a 
33% prevalence (Assy et al 2000).
Pathogenesis
The pathologic sequence of events from steatosis (ie, the 
“ﬁ  rst hit”), to steatohepatitis to cirrhosis is well established 
(Powell et al 1990; Bacon et al 1994) (Figure 1). However, 
fat, per se is not hepatotoxic (Teli et al 1995; Dam-Larsen 
et al 2004; Adams et al 2005). Why some patients progress 
and most do not is not known. It is now widely accepted that 
a “second hit” is necessary for NAFLD to progress to NASH 
and cirrhosis. What is common to virtually all patients with 
NAFLD is insulin resistance. It remains uncertain if this is 
a primary or secondary event to steatosis.
The presence of insulin resistance and/or obesity permits/
promotes disease progression (Clark et al 2002; Bellentani 
et al 2004). They also seem to promote susceptibility to 
additive injury from alcohol (You and Crabb 2004) and 
hepatitis C (Patel et al 2005). The clinical features which 
support progression are increasing age (45 years), increas-
ing BMI (30), reversed ALT/AST ratio and elevated serum 
triglycerides (Angulo et al 1999). The mechanisms remain 
somewhat speculative but a unifying concept of the patho-
physiologic events is now evolving and these are pertinent 
as therapeutic targets (Figure 2).
Steatosis reﬂ  ects a net retention of fat within hepatocytes 
and results from an imbalance between uptake of fat and its 
oxidation and export. The most consistent pathogenic factor 
is insulin resistance, leading to enhanced lipolysis which in 
turn increases circulating free fatty acids and their uptake 
by the liver (Marchesini et al 1999). Fat accumulating in 
the liver has several effects: (1) upregulation of apoptosis 
(Feldstein et al 2003a, 2003b), (2) indirect upregulation of 
TNFα which is pro-steatotic and pro-inﬂ  ammatory (Diehl 
2004; You and Crabb 2004), (3) mitochondrial dysfunction 
(Perez-Carreras et al 2003; Feldstein et al 2004; Kharroubi 
et al 2004; Begriche et al 2006) presumably increasing reac-
tive oxygen species (ROS) and provoking lipid peroxidation 
of cell membranes, (4) induction of CYP 2E1 which gener-
ates ROS (Weltman et al 1998; Nieto et al 2002; Chalasani 
et al 2003), (5) induction of pro-inﬂ  ammatory genes such as 
TNFα (Samuel et al 2004; Arkan et al 2005; Cai et al 2005), 
and COX2 which induce additional inﬂ  ammatory mediators 
which are also pro-ﬁ  brotic (Nieto et al 2000). The net effect 
of the above is apoptosis, necroinﬂ  ammation and ﬁ  brosis.
Hepatic ﬁ  brosis is promoted by steatosis even in the 
absence of liver cell injury (Reeves et al 1996). Adipokines, 
hormones secreted by adipocytes, appear to be important 
regulators of hepatic ﬁ  brosis. Leptin, which is increased in 
the metabolic syndrome, promotes ﬁ  brosis and induces pro-
inﬂ  ammatory cytokines (Saxena et al 2002, 2004; Alefﬁ   et al 
2005) while adiponectin, which is decreased in metabolic 
syndrome, inhibits stellate cell activation. The net affect of 
increased leptin and decreased adiponectin is pro-inﬂ  ammatory 
and pro-ﬁ  brotic. Finally, activation of the renin-angiotensin 
system is a characteristic feature of the metabolic syndrome 
(Prasad and Quyyumi 2004). Angiotensin II, the most active 
mediator of this system, activates hepatic stellate cells and 
Table 1 Causes of non-alcoholic fatty liver disease
Nutritional Drugs
 Starvation   Glucocorticoids
 Obesity*   Tamoxifen
 Bariatric  surgery   Amiodarone
  Parenteral nutrition    Valproic acid
 Celiac  disease   Zidovudine
Metabolic   Didanosine
 Insulin  resistance*  Other
 Dyslipidemia*   Inﬂ  ammatory bowel disease
  Fatty liver of pregnancy    Halogenated hydrocarbons
    Toxic  mushrooms
* Most common causes.Therapeutics and Clinical Risk Management 2007:3(6) 1155
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Figure 1 The natural history of non-alcoholic fatty liver disease.
Figure 2 Unifying concept of the pathogenesis of NAFLD. ROS = reactive 
oxygen species, TG = triglycerides, VLDL = very low density lipoprotein, 
CYP = cytochrome P450.
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active collagen synthesis (Bataller, Gabele et al 2003; Bataller, 
Schwabe et al 2003; Bataller et al 2005).
Taken together these observations account for the char-
acteristic histologic features of NASH (steatosis, apoptosis, 
inﬂ  ammation and ﬁ  brosis) and provide important targets for 
therapy. A unifying concept of the pathophysiology is shown 
in Figure 2. In summary, insulin resistance leads to hyper-
insulinemia which in turn leads to lipolysis of peripheral fat 
with mobilization of fatty acids to the liver. The fatty acids are 
substrate for ß-oxidation as an energy source. In some patients, 
ie, those with NASH, reactive species are formed leading to 
oxidative stress with cell damage, inﬂ  ammation and ﬁ  brosis.
Diagnosis
Most patients with NAFLD/NASH are asymptomatic or have 
only mild fatigue or slight right upper quadrant abdominal 
discomfort. The diagnosis should be suspected in anyone 
with the conditions listed in Table 1. The goals of evalua-
tion are threefold: (1) establish a diagnosis of NAFLD, (2) 
determine the etiology, and (3) determine if there is progres-
sive disease (ie, NASH). The gold standard for establishing 
a diagnosis of NAFLD and distinguishing it from NASH is 
the liver biopsy. A number of histologic scoring systems 
have been developed although none have been universally 
accepted (Kleiner et al 2005; Mendler et al 2005) (Table 2). 
The Pathology Committee of the NASH Clinical Research 
Network has devised a system derived from multiple logistic 
regressions and scored as the unweighted sum of scores of 
steatosis (0–3), lobular inﬂ  ammation (0–3) and ballooning 
(0–2). NASH is deﬁ  ned as a score of 5 (Kleiner et al 2005). 
Another scoring system includes scores for fatty change 
(1–4), portal ﬁ  brosis (0–6) and activity comprising lobular 
inﬂ  ammation (0–3), Mallory bodies (0–3), hepatocyte bal-
looning (0–3) and perisinusoidal ﬁ  brosis (0–3) (Mendler et al 
2005). The latter system has the advantage of scoring ﬁ  brosis. 
All scoring systems are compromised by sampling error with 
a discordance rate of 18% in one study (Ratziu et al 2005). 
Furthermore, it is not possible to distinguish alcoholic from 
non-alcoholic fatty liver disease on histologic grounds and 
the distinction continues to be made by clinical criteria ie, 
less than or greater than 20 gms of alcohol per day. Liver 
biopsy is costly, invasive, and subject to sampling error. The 
search for non-invasive techniques continues.
Ultrasound has an overall sensitivity of 89% with 93% 
speciﬁ  city (Joseph et al 1991) but falls off greatly in those 
with mild disease or ﬁ  brotic disease when the amount of fat 
in the liver is less than 30% (Siegelman and Rosen 2001; 
Neuschwander-Tetri and Caldwell 2003). The characteristic Therapeutics and Clinical Risk Management 2007:3(6) 1156
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ultrasonic feature is the “bright” liver with increased paren-
chymal echo texture and vascular blurring. Areas of focal 
sparring can give the appearance of metastases (Mitchell 
1992). The positive and negative predictive value of ultra-
sound in patients with abnormal liver chemistries and other 
causes of liver disease ruled out is 96% and 19% respectively. 
The value of ultrasound as a screening test has not been 
established and, given its low negative predictive value, it 
seems unlikely that it will be. Ultrasound is further compro-
mised by an inability to detect ﬁ  brosis (Saadeh et al 2002; 
Neuschwander-Tetri and Caldwell 2003). Non-invasive 
methods for detecting ﬁ  brosis have not yet surfaced for 
routine clinical use.
Factors which are predictive of fibrotic disease are 
reversed ALT/AST ratio, hypoalbuminemia, elevated pro-
thrombin time and thrombocytopenia (Angulo et al 1999; 
Sorbi et al 1999). Clinical features such as ascites, esophageal 
varices, coagulopathy and encephalopathy are consistent with 
cirrhosis. Biopsy in such patients is not helpful and does not 
distinguish cirrhosis from other causes.
The search for etiology should include a serum lipid 
panel, a test for insulin resistance and a history of potential 
drug causes.
Treatment
Treatment falls into two categories: targeting either the 
steatosis or the pathogenesis of progression. There are no 
FDA approved pharmacologic agents and, in fact, no FDA 
guidelines for such drugs despite the fact that NAFLD is the 
most common liver disease in the US. The treatments used to 
date are outlined in Table 3. Virtually all are compromised 
by small numbers and lack of placebo control.
Treatment of steatosis/insulin resistance
The treatment of steatosis is inexorably linked to obesity, 
insulin resistance and dyslipidemia. In general, factors that 
decrease steatosis consist of weight loss or pharmacologic 
therapy directed at insulin resistance or dyslipidemia. The 
treatment of steatohepatitis is directed at oxidative stress, 
inﬂ  ammation and ﬁ  brosis. Factors that decrease oxidative 
stress and inﬂ  ammation include antioxidants, probiotics, 
anti-cytokines and glutathione precursors. Anti-fibrotic 
therapy is in its infancy.
Weight loss
Weight loss improves liver chemistries, steatosis, necro-
inflammatory changes and fibrosis (Huang et al 2005; 
Petersen et al 2005; Suzuki et al 2005). Furthermore, gradual 
weight reduction has been shown to lower insulin levels 
and improve quality of life (Petersen et al 2005). Weight 
loss may be achieved through diet and exercise or bariatric 
surgery.
Diet
The ideal diet and rate of weight loss is yet to be determined 
although it is known that rapid weight loss may exacerbate 
disease (Andersen et al 1991). A number of studies, both con-
trolled and uncontrolled, indicate that weight loss decreases 
hepatic steatosis (Huang et al 2005; Petersen et al 2005; 
Suzuki et al 2005). The durability of weight loss on hepatic 
steatosis remains to be determined. Low fat diets should 
be avoided (Solga et al 2004; Kang et al 2006). Some have 
suggested that a Mediterranean diet (ie, high consumption 
of complex carbohydrates and monounsaturated fat, low 
amounts of red meat, and low/moderate amounts of wine) 
is preferred (Musso et al 2003; Esposito et al 2004). A low 
glycemic, low calorie diet with a weight loss of 1–2 kg/wk 
seems reasonable.
Bariatric surgery
Bariatric surgery, recently reviewed by Angulo (2006) has 
proved successful in a number of studies (Dixon et al 2004; 
Clark et al 2005; Mattar et al 2005; Barker et al 2006; Klein 
et al 2006; Mathurin et al 2006) The formerly used ileal 
bypass surgery was, however, associated with fatty liver and 
even hepatic failure (Marubbio et al 1976). The durability of 
bariatric surgery has yet to be determined but it seems likely 
to be the only therapy that will change the natural history of 
NASH (Angulo 2006).
Orlistat
Orlistat is a lipase inhibitor that promotes weight loss by 
reduction of fat absorption. A trial by Harrison et al (2004) 
in 10 patients reported a mean weight loss of 10 kg with 6 
months of treatment. Aminotransferases improved during 
treatment. No change in histology was reported. Another 
double blind, placebo-controlled trial by Zelber-Sagi et al 
Table 2 Types of NAFLD by histology and outcome
Category Histology  Outcome
Type 1  steatosis only  non-progressive
Type 2  steatosis plus  benign course
 lobular  inﬂ  ammation
Type 3  steatosis, lobular inﬂ  ammation  NASH without ﬁ  brosis,
  and ballooning degeneration  may progress to cirrhosis
Type 4  steatosis, ballooning  NASH, may progress to 
  degeneration with Mallory  cirrhosis
 bodies  and/or  ﬁ  brosisTherapeutics and Clinical Risk Management 2007:3(6) 1157
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(2006) randomized 52 patients with NAFLD (diagnosed 
by ultrasound and conﬁ  rmed with biopsy) to orlistat or 
placebo for 6 months. Orlistat decreased aminotransferase 
levels and reversed fatty liver as determined by ultrasound. 
Similar results were seen in another open label trial of 
12 nonrandomized, obese patients with NASH (Sabuncu 
et al 2003), although alkaline phosphatase levels increased 
during therapy. Orlistat has recently become available over 
the counter in the US. The side effects of gas, bloating and 
steatorrhea are problematic.
Table 3 Summary of interventions in NAFLD
Treatment Ref  N  Study  Design  ALT/AST  Histology    US/MRI
         Steatosis  Inﬂ  ammation/ﬁ  brosis
Steatosis/Insulin Resistance
Weight loss   Huang et al 2005  23  CS  U  U  U  ND
Weight loss  Suzuki et al 2005  348  CS  I  ND  ND  ND
Weight loss   Petersen et al 2005  8  C  ND  I  ND  I
Bariatric surgery   Barker et al 2006  19  CS  ND  I  I  ND
Bariatric surgery   Mattar et al 2005  70  CS  ND  I  I  ND
Bariatric surgery   Dixon et al 2004  36  CS  ND  I  I  ND
Bariatric surgery   Clark et al 2005  16  CS  ND  I  I  ND
Bariatric surgery   Klein et al 2006  7  CS  U  I  U  U
Bariatric surgery   Mathurin et al 2006  185  CS  I  I  I  ND
Orlistat   Harrison et al 2004  10  CS  I  U  U  ND
Orlistat  Zelber-Sagi et al 2006  52  R, DB, PC  ND  ND  ND  I
Orlistat   Sabuncu et al 2003  12  CS  I  ND  ND  I
Sibutramine   Sabuncu et al 2003  13  CS  I  ND  ND  I
Pioglitazone   Promrat et al 2004  18  CS  I  I  I  I
Pioglitazone   Sanyal et al 2004  10  R, C  U  U  I  ND
Pioglitazone  Belfort et al 2006  55  R, B, PC  I  I  I  I
Rosiglitazone   Neuschwander-Tetri et al 2003  30  CS  I  I  I  I
Rosiglitazone   Ratziu et al 2006  63  R, DB, PC  I  ND  I  ND
Metformin   Marchesini et al 2001  14  C  I  ND  ND  ND
Metformin  Uygun et al 2004  17  R, C  I  U  U  I
Metformin  Schwimmer et al 2005  10  CS  I  ND  ND  ND
Atorvastatin   Horlander et al 2001  7  CS  U  U  I  ND
Atorvastatin   Kiyici et al 2003  27  CS  I  I  ND  I
Pravastatin   Rallidis et al 2004  5  CS  I  ND  I  ND
Rosuvastatin  Antonopoulos et al 2006  23  CS  I  ND  ND  ND
Gemﬁ  brozil  Basaranoglu, Acbay et al 1999  23  R, C  I  ND  ND  ND
Apoptosis
Ursodiol  Laurin et al 1996  24  R, C  I  I  U  ND
Ursodiol   Kiyici et al 2003  27  CS  I  I  U  U
Ursodiol  Lindor et al 2004  80  R, B, PC  U  U  U  ND
Oxidative Stress/Inﬂ  ammation: Antioxidants
Vitamin E   Lavine 2000  11  CS  I  ND  ND  ND
Vitamin E & C   Harrison et al 2003  23  R, DB, PC  U  ND  U  ND
Vitamin E  Bugianesi et al 2005  28  R, C  I  ND  ND  ND
Oxidative Stress/Inﬂ  ammation: Pro-biotics/Pre-biotics
VSL#3  Loguercio et al 2005  22  CS  I  ND  ND  ND
Oxidative Stress/Inﬂ  ammation: Anti-cytokines
Pentoxifylline   Adams et al 2004  20  CS  I  ND  ND  ND
Pentoxifylline  Satapathy et al 2004  18  CS  I  ND  ND  ND
Pentoxifylline   Lee et al 2006  11  R, DB, PC  U  ND  ND  ND
Oxidative Stress/Inﬂ  ammation: Glutathione Precursors
Betaine   Abdelmalek et al 2001  10  CS  I  U  I  ND
Betaine  Abdelmalek et al 2006  55  R, PC  U  ND  U  ND
Fibrosis
Losartan  Yokohama et al 2004, 2006  7  CS  I  U  I  ND
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; B, blinded; C, controlled; CS, case series; DB, double-blinded; I, improved; MRI, magnetic 
resonance imaging; ND, no data; PC, placebo-controlled; R, randomized; U, unchanged; US, ultrasound.Therapeutics and Clinical Risk Management 2007:3(6) 1158
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Sibutramine
Sibutramine, an appetite suppressant, is a serotonin reuptake 
antagonist approved for weight loss. It also has been studied 
in patients with NAFLD. It signiﬁ  cantly improved amino-
transferases in 13 of 13 patients and decreased evidence of 
hepatic steatosis on ultrasound in 11 of 13 patients in an open 
label, nonrandomized study (Sabuncu et al 2003). These 
patients were all obese and were diagnosed with NASH. 
Alkaline phosphatase levels increased during therapy.
Pharmacologic therapy
Thiazolidinediones
Thiazolidinediones (TZDs) are PPARγ agonists which 
increase insulin sensitivity and increase the number and acti-
vation of adipocytes (Shulman 2000). This leads to a redis-
tribution of lipids from liver and muscle cells to adipocytes 
which, in turn, restores insulin sensitivity (Shulman 2000; 
Bajaj et al 2004). They also increase adiponectin expression, 
decrease TNFα expression, (Iwata et al 2001; Hernandez 
et al 2004) and reduce collagen synthesis (Galli et al 2002). 
The net effect of PPARγ agonists is an increase in insulin 
sensitivity, a redistribution of fat from liver to adipocytes and 
a reduction in hepatic ﬁ  brosis. Animal studies have conﬁ  rmed 
these observations (Jia et al 2000; Galli et al 2002) and human 
trials are beginning to conﬁ  rm the beneﬁ  cial effects (Caldwell 
et al 2001). In the initial study using troglitazone, 7 of 10 
patients showed improvement in ALT after 6 months. There 
was, however, no histologic improvement and troglitazone 
was removed from the market because of hepatotoxicity. 
Subsequent trials with pioglitazone and rosiglitazone have 
not shown evidence of hepatotoxicity.
Pioglitazone
Three small trials and a large controlled trial have evalu-
ated pioglitazone in the treatment of NAFLD (Shadid and 
Jensen 2003; Promrat et al 2004; Sanyal et al 2004; Belfort 
et al 2006). A 48 week trial of pioglitazone, 30 mg daily, in 
18 patients by Promrat et al (2004) showed improvement in 
ALT and histology. Fibrosis decreased in 61% and remained 
stable in 22%. A 6 month controlled trial by Sanyal et al 
(2004) of 20 patients compared vitamin E (400 I.U./d) to 
pioglitazone (30mg/day) plus vitamin E. The combination 
showed improvement in insulin sensitivity and histology.
In the largest controlled trial to date with pioglitazone, 
Belfort et al compared diet plus pioglitazone to diet plus 
placebo in 55 patients (Belfort et al 2006). The pioglitazone 
group showed signiﬁ  cant improvement in ALT (by 58%), 
hepatic fat content (by 54%) and insulin sensitivity (by 48%). 
There was signiﬁ  cant histologic improvement in steatosis, 
ballooning necrosis and inﬂ  ammation but not ﬁ  brosis.
Rosiglitazone
There have been 3 trials, including a placebo controlled trial, 
with rosiglitazone (Neuschwander-Tetri et al 2003; Tiikkai-
nen et al 2004; Ratziu et al 2006). In the ﬁ  rst of these studies 
(Neuschwander-Tetri et al 2003), 30 patients were treated 
with rosiglitazone 8mg daily for 48 weeks. There was signiﬁ  -
cant improvement in ALT, AST, GGT and insulin sensitivity. 
Of the 22 patients who had histologic evaluation, steatosis 
improved in 13 and worsened in one; ﬁ  brosis score improved 
in 8 and worsened in 3. This study was confounded by the use 
of statins. The results of the 63 patient, French multicenter 
placebo controlled trial known as FLIRT have just been 
presented (Ratziu et al 2006). There was improvement in 
histology (47%) compared to placebo (16%) and ALT (38%) 
versus placebo (7%). Interestingly, the non-diabetic patients 
did better than the diabetic patients in this study.
In summary, several trials have shown a beneﬁ  cial effect 
of TZDs in patients with insulin resistance syndrome/DM2. 
Issues about hepatotoxicity have been dispelled (Tolman and 
Chandramouli 2003) and there is evidence that the use of 
TZDs in patients with elevated baseline liver chemistries is 
safe (Chalasani et al 2005). It is yet to be determined if there 
are long-term beneﬁ  ts. However, there has been consistent 
short-term beneﬁ  t in surrogate (serum ALT) and histologic 
markers. TZDs, despite their shortcomings, are emerging as 
the drugs of choice for treating diabetic patients with NASH. 
However, as recently stated by McCullough (2006), the best 
description of TZDs for NASH may be, “Promising but not 
ready for prime time”.
Metformin
Metformin is a biguanide that stimulates ß-oxidation in the 
mitochondria (DeFronzo et al 1991). It also suppresses lipo-
genic enzymes. In so doing it bypasses insulin resistance by 
utilizing fatty acids as an energy source. It is in this way that 
it reduces hyperinsulinemia (Stumvoll et al 1995; Cusi et al 
1996). Animal studies in ob/ob mice with fatty liver disease 
have shown improvement in steatosis and aminotransferase 
abnormalities (Lin et al 2000). Human trials have been less 
convincing. Three small trails resulted in a signiﬁ  cant reduc-
tion in aminotransferase levels (Marchesini et al 2001; Uygun 
et al 2004; Schwimmer et al 2005). One of the trials showed 
enhanced insulin sensitivity and a transient improvement 
in serum aminotransferase levels (Marchesini et al 2001). 
In another trial, metformin and diet were compared to diet Therapeutics and Clinical Risk Management 2007:3(6) 1159
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alone over 6 months. A statistically signiﬁ  cant reduction in 
ALT, insulin and C-peptide was detected. There was also 
an improvement in necroinﬂ  ammation that did not reach 
statistical signiﬁ  cance (Uygun et al 2004). The increase 
in anaerobic respiration and potential for lactic acidosis is 
more a theoretical than actual concern except in patients with 
alcoholism and underlying renal insufﬁ  ciency. Long term 
beneﬁ  ts and histologic beneﬁ  t have not been demonstrated. 
At the present time, metformin cannot be recommended for 
non-diabetic patients with NASH.
Statins
Statins are currently used to treat NAFLD (Horlander et al 
2001; Kiyici et al 2003; Rallidis et al 2004; Antonopoulos 
et al 2006). Recent studies suggest that statins are hepa-
toprotective in patients with other forms of liver disease 
including hepatitis C (Chalasani et al 2004). Statins may 
reduce hepatic fat content in patients with hyperlipidemia 
and NASH (Horlander et al 2001; Kiyici et al 2003). To 
date, atorvastatin, pravastatin, and rosuvastatin have been 
studied. An important point about these studies is that the 
statin doses were not equipotent nor comparable in their 
lipid lowering effect.
Atorvastatin was compared with ursodeoxycholic acid 
in a small trial of 44 obese adults with NASH, including 10 
patients with diabetes (Kiyici et al 2003). In the statin arm 
of the study, hyperlipidemic patients received atorvastatin 
10 mg daily for 6 months. Liver chemistries improved and 
an increase in liver density, suggesting a decrease in fat 
content, occurred in the atorvastatin group.
Two other statins have been evaluated in patients 
with NAFLD. Pravastatin, at a dose of 20 mg daily for 
6 months, normalized liver enzymes and improved hepatic 
inﬂ  ammation in 5 of 5 patients (Rallidis et al 2004). 
Rosuvastatin was studied in 23 patients with hyperlipid-
emia and biochemical and ultrasound evidence of NAFLD 
(Antonopoulos et al 2006). After 8 months of rosuvastatin 
10 mg daily, all patients had normal ALT and AST and 
all achieved LDL goals. Histology was not evaluated. 
In summary, further studies are needed but statins are 
promising agents for the treatment of NASH as well as 
other liver diseases.
Fibric acid derivatives
Gemﬁ  brozil, 600 mg daily for 1 month, has been studied in 
a randomized, controlled study of 46 patients with NAFLD. 
The ALT normalized over this period, but histologic changes 
were not evaluated (Basaranoglu, Acbay et al 1999). The dose 
of gemﬁ  brozil in this trial was less than the labeled dose of 
1200 mg per day.
Treatment of pathophysiologic 
mechanisms
There is increasing interest in treating NASH by targeting 
the pathophysiologic mechanisms.
Apoptosis
Apoptosis is an important mechanism of cell death in 
NAFLD.
Ursodeoxycholic acid
Ursodiol (ursodeoxycholic acid) is an anti-apoptotic, cyto-
protective, immune-modulating, anti-inﬂ  ammatory agent that 
is widely used in liver disease. The results of initial studies 
varied, but some showed promising results in improving ALT 
(Laurin et al 1996; Kiyici et al 2003) while others reported 
no signiﬁ  cant difference in ALT (Vajro et al 2000; Lindor et 
al 2004). In one of the studies, ursodiol did show improve-
ment in steatosis, but no improvement in inﬂ  ammation or 
ﬁ  brosis (Laurin et al 1996). All of these studies were small 
(17 to 24 patients) and had no comparator group. To further 
study ursodiol, a randomized, placebo controlled trial involv-
ing 166 patients with NASH compared ursodiol to placebo 
for 2 years (Lindor et al 2004). Liver function tests improved 
in both groups; however, signiﬁ  cant differences were not 
detected between placebo and ursodiol. Histologic changes 
(steatosis, necroinﬂ  ammation, or ﬁ  brosis) also were not sig-
niﬁ  cantly different between the ursodiol and placebo groups. 
At the present time, ursodiol cannot be recommended. Studies 
are underway using it as add-on therapy.
Oxidative stress/inﬂ  ammation
Antioxidants
Oxidative stress is important in the pathogenesis of NASH, 
and antioxidants (vitamin E) may decrease levels of proﬁ  -
brinogenic TGF-β, improve histology, and inhibit hepatic 
stellate cell activation.
Vitamin E/vitamin C
Pilot studies with vitamin E have been conducted (Lavine 
2000; Hasegawa et al 2001; Harrison et al 2003; Sanyal et al 
2004; Bugianesi et al 2005) with promising results in reduc-
ing aminotransferases. One randomized placebo controlled 
trial looked at the combination of vitamin E and vitamin C 
(Harrison et al 2003). Improvement in hepatic inﬂ  ammation 
and ﬁ  brosis was detected. However, these differences were Therapeutics and Clinical Risk Management 2007:3(6) 1160
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not signiﬁ  cantly different from the placebo arm. A recent open 
label study compared vitamin E to metformin and weight loss 
(Bugianesi et al 2005). Vitamin E was inferior to metformin 
and/or weight loss in improving aminotransferases.
A recent meta-analysis of high dose vitamin E in the 
general population revealed an increase in overall mortality 
(Miller et al 2005). Due to the possible increase in mortal-
ity with general use of antioxidants and the mixed results 
from clinical trials in NASH, the use of antioxidants is not 
recommended.
Pro-biotics/pre-biotics
Probiotics may reduce hepatic injury in animal models where 
intestinal derived bacterial endotoxin sensitizes fatty livers to 
the effects of TNF-α. A 3-month treatment period of a com-
mercially available probiotic, VSL #3, given to 22 patients 
with NAFLD did improve ALT levels and markers of lipid 
peroxidation (Loguercio et al 2005). Histology was not 
evaluated in this trial.
Anti-cytokines
Pentoxifylline
TNF-α is a pro-inﬂ  ammatory cytokine that triggers the pro-
duction of additional cytokines that recruit inﬂ  ammatory cells 
and leads to the destruction of hepatocytes and induction of 
ﬁ  brogenesis. This cytokine is increased in NASH. Pentoxifyl-
line is a methylxanthine compound that inhibits TNF-α and 
is a promising agent in the treatment of alcoholic hepatitis. 
A pilot study in 20 cpatients detected improvement in liver 
enzymes in patients with NASH (Adams et al 2004). How-
ever, the high incidence of gastrointestinal side effects led 
to early withdrawal in many patients. Satapathy et al (2004) 
found that pentoxifylline reduced mean transaminase levels, 
reduced serum TNF-α levels, and improved insulin resistance 
in 18 patients over a 6 month period. Another trial by Lee et al 
(2006) studied 20 patients with NASH and randomized them 
to 3 months of pentoxifylline or placebo. Both groups had 
signiﬁ  cant decreases in BMI and aminotransferase levels, but 
there were no signiﬁ  cant differences between groups. More 
patients who received pentoxifylline achieved normal AST. 
Both groups reported a signiﬁ  cant decrease in TNF-α, Il-6, 
Il-8, and serum hyaluronic acid.
Glutathione precursors
Betaine
Betaine is a component of the metabolic cycle of thionine 
and may increase S-adenosylmethionine levels. This process 
may protect against steatosis in alcoholic liver disease 
animal models. A small, 1-year trial showed that betaine 
significantly improved aminotransferase levels versus 
baseline (Abdelmalek et al 2001). In addition, a marked 
improvement in the degree of steatosis, necroinﬂ  ammatory 
grade, and stage of ﬁ  brosis was observed. Abdelmalek et al 
(2006) then conducted a placebo-controlled, 12-month trial 
of 55 patients and reported that betaine did not signiﬁ  cantly 
improve aminotransferases or liver histology.
Fibrosis
Animal studies have shown that angiotensin II promotes 
insulin resistance and hepatic ﬁ  brosis.
Angiotensin II receptor antagonists
Lorsartan
Losartan, an angiotensin II receptor antagonist, has been used 
in two studies (Yokohama et al 2004, 2006). In an histori-
cally controlled study (Yokohama et al 2004, 2006), losartan 
50 mg daily was associated with improved aminotransferases, 
serum markers of ﬁ  brosis, and plasma TGF-β1. Histologi-
cal improvements were detected in several of the patients: 
necroinﬂ  ammation (5 patients), reduction of hepatic ﬁ  brosis 
(4 patients), and reduced iron disposition (2 patients).
Summary
There is increasing understanding of the risk factors for 
NAFLD and its underlying pathophysiology. New therapies 
are evolving but weight loss remains the mainstay of therapy. 
Targeted pharmacologic therapy is evolving in the treatment 
of the underlying pathophysiologic events of steatosis, apop-
tosis, oxidative stress and ﬁ  brosis. The thiazolidinediones, 
have shown promising results in the reduction of steatosis 
and, perhaps, the progression to cirrhosis. However, further 
controlled clinical trials are needed before any speciﬁ  c 
therapy other than weight loss and exercise can be recom-
mended without reservation. Patients with insulin resistance 
can be treated with thiazolidinediones while patients with 
dyslipidemia can be treated with lipid lowering agents.
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